INCY.US Incyte Corporation

Healthcare Biotechnology USA Stocks
120.97 USD
Close of Nov 15, 2026
89.25 132.60
Market cap
USD 24.7B
P/E
61.7x
P/B
4.37x
ROE
2.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INCY.US undervalued?

Graham number

The Graham number of Incyte Corporation cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Incyte Corporation fundamental analysis

No fundamental analysis for Incyte Corporation yet.

Incyte Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/MINJUVI for the treatment…

Full company profile